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Why was the cohort consortium set up?
Nausea and vomiting during pregnancy (NVP), commonly
known as morning sickness, is very common and is typic-
ally self-limiting. However, more severe forms and the de-
velopment of hyperemesis gravidarum (HG), defined as
persistent and excessive vomiting, with dehydration, keto-
nuria and >5% bodyweight loss,1 may lead to health con-
sequences for the mother and the offspring exposed in
utero. Despite efforts towards understanding the causes of
NVP and HG, they are not well established. The NVP
Genetics Consortium is an open collaborative network of
researchers integrating data on NVP of women who have
been pregnant at least once, with the goal of investigating
NVP, NVP severity and HG. Currently, the NVP Genetics
Consortium brings together data from Australia, Finland,
Spain, the UK and Denmark. The Consortium is actively
recruiting new members.
Early consortium efforts started at the QIMR Berghofer
Medical Research Institute (QIMR), Brisbane, Australia,
including the collection of data in three different samples
from ongoing studies: the QIMR NVP study, the
Australian Endogene Study (QIMR AES) and the QIMR
Mothers of Twins (QIMR MT) study. The QIMR NVP
study was specifically designed as a comprehensive data
collection on NVP. The two other studies asked questions
about NVP as part of other health-related projects. In
2013, the Genetics of Sexuality and Aggression twin sam-
ples (GSA, A˚bo Akademi University in Finland) and the
Murcia Twin Registry (MTR, University of Murcia in
Spain), introduced questions on NVP in their protocols
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with the aim of participating in this project. In 2014, the
Avon Longitudinal Study of Parents and Children
(ALSPAC, University of Bristol in England), and in 2015,
the Danish National Hospital Register (DNHR, in
Denmark) began collaborating with data on NVP and HG
that were already available. Currently, each study group
has independent funding and shares summary statistics on
the questions of interest.
Meta-analysis has shown that around 70% of pregnant
women worldwide experience some symptoms of NVP2
with different degrees of severity. It is estimated that 1.1%
of women suffer HG. A recent systematic review highlights
that mild/moderate NVP is associated with favourable fetal
outcome in terms of decreased risk of miscarriages, con-
genital malformations, prematurity and developmental
achievements.3 However, NVP affects the physical health
of pregnant women and can also affect their psychosocial
functioning, with consequences in both personal and pro-
fessional domains4 that may result in a lower health-
related quality of life.5 Severe NVP and HG are risk factors
for postnatal depression.6,7 NVP and HG also entail eco-
nomic costs, estimated at almost 1.8 billion USD in the
USA in 2012.8
The aetiology of NVP appears to be multifactorial.
Several lines of evidence support a genetic predisposition
to NVP and HG.9–11 There is one published twin study on
the topic, conducted in the population-based Norwegian
Twin Panel,9 showing higher correlations of occurrence of
NVP and taking nausea medication during pregnancy for
monozygotic twins than for dizygotic twins. Genetic vari-
ants influencing the human chorionic gonadotrophin hor-
mone, serotonin and autoimmune functioning have been
proposed as candidates for NVP.12,13 It has also been pro-
posed that there is a higher frequency of severe NVP in pa-
tients with disorders in taste sensation, in the glycoprotein
hormone receptor or in fatty acid transport.14–18
The general aim of the NVP Genetics Consortium is to
add knowledge to the characterization of the genetic, but
also the environmental, risk factors for HG as well as NVP
occurrence and severity, in order to facilitate development
of novel therapeutics and more individualized health inter-
ventions. Our specific objectives are: (i) to increase the
knowledge of the relative impact of genetic vs environmen-
tal causes of HG, NVP and NVP severity; (ii) using gen-
ome-wide association studies (GWASs), to identify genetic
or genetically influenced risk factors for these phenotypes;
and (iii) to elucidate the socio-demographic, health- and
lifestyle-related factors accounting for individual differ-
ences in these disorders, with special attention to psycho-
logical variables.
To address the first of our aims, the two twin samples
that are part of the Consortium will conduct a joint twin
analysis to estimate the heritability and the genetic correl-
ation between phenotypes related to NVP. Large sample
sizes, assembled by the Consortium, will enable us to
search for genetic variants involved in NVP/HG using
GWAS19 and bioinformatic analyses of pathway and regu-
latory networks will clarify the relationships between can-
didate and novel genetic risk factors. Meta-analysis will
allow us to maximize power while explicitly checking for
the presence of latent population substructure/ethnicity or
sample/genotype based artefacts through heterogeneity
tests. Likewise the combined summary statistics will allow
us to maximize power for multivariate linkage disequilib-
rium (LD) score regressions to estimate the extent to which
the genetic correlation between NVP traits can be ex-
plained by common variants.20 The third of our questions
will be addressed with cross-sectional analyses among co-
horts that will examine social risk factors and epidemiolo-
gical data. Additionally, the twin studies will estimate the
amount of variance explained by psychosocial and envir-
onmental risk factors. To aid in the interpretation of sig-
nificant results, targeted follow-up analyses will examine
the effect of parity and potential covariates.
We expect our collaborative work will result in a better
prediction of which women will be at risk for NVP and
HG and the development of more effective interventions
along with treatments that will directly prevent the pro-
gression from moderate to severe NVP or HG.
Who is in the cohort?
Currently, the NVP Genetics Consortium incorporates
data on approximately 13 640 women reporting NVP and
3116 reporting no experience of NVP from the Australian,
Finnish, Spanish and British samples, and around 9074
women suffering from HG as recorded by the Danish
Register within a population-based cohort of 565 486
women (the reminder of which will serve as controls).
Differences in data collection across the cohorts have led
to the adoption of broad phenotypic definitions (e.g. expe-
riencing NVP or not). With the exception of QIMR NVP,
all the samples are unselected with regards to the pheno-
type of interest. Two of the studies (Finnish and Spanish)
are twin cohorts. Sample sizes, age at the time of the survey
and a summary of the availability of the main variables on
NVP/HG collected across the cohorts, are provided in
Table 1.
The QIMR NVP study was specifically launched for a
comprehensive data collection on NVP through an online
survey, starting in 2013 and currently ongoing. It follows a
self-selected sampling strategy to collect data from women
who have suffered from NVP as inclusion criterion. This
strategy over-samples cases in order to create an extreme
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study design. Currently, 933 women have completed the
survey and the goal is to reach data of around 1300
women with severe NVP. We aim to collect 1000 saliva
samples in a second stage of this study. Women are being
recruited via media appeals and postings to pregnancy/par-
enting forums. The second QIMR Berghofer sample,
QIMR AES, consists of 1400 women who were ap-
proached for a larger study on common health conditions.
In 2012, women previously recruited for a study on endo-
metriosis21 were contacted by letter or email and invited to
complete an online questionnaire, including questions
about NVP. The response rate was 81%. The QIMR MT
cohort comprises the mothers of adolescent twins who
are taking part in the Brisbane Adolescent Twin Study.
The mothers are approached when the twins are assessed
at QIMR Berghofer. The response rate is 97% and, to
date, 296 women have participated. Of these partici-
pants, 90.54% have also given birth to singletons, so the
QIMR MT sample confers an opportunity to study in
more depth the development of NVP in twin pregnancies,
which are risk factors for both NVP and HG,22–24 and
the experience of NVP in singleton pregnancies in the
same women.
The GSA project consists of a large, population-based
twin cohort launched at the Abo Akademi University
(Finland), first assembled in 2005–06 (see refs25,26 for a
detailed description of the original data collections). Data
on NVP were collected in 2013 from a subsample of fe-
male twins and female siblings of twins, which represents a
longitudinal data collection—although longitudinal data
arecurrently not available for NVP. The subsample
included in the NVP Genetics Consortium consists of 1368
women who have reported being pregnant at least once,
with 296 being an MZ twin (41 complete pairs), 587 a DZ
twin (313 are DZ same-sex twins, 37 DZ complete pairs),
25 twins of undefined zygosity and 460 sisters of twins.
Data were collected in 2013 by a secure, online question-
naire, and zygosity was determined by genotyping and
questionnaire. Response rate to the 2013 questionnaire
was 43.5%.
The MTR sample is population-based and consists of
all twin pairs born between 1940 and 1966, with adminis-
trative residence in the Region of Murcia, in Southeast
Spain (MTR; see refs27,28). For the NVP Genetics
Consortium, the MTR has provided data on 551 women
consisting of 294 from MZ twin pairs and 257 from DZ
same-sex twin pairs. The response rate in this sample was
close to 75%. Zygosity was determined by questionnaire
and DNA testing, using short tandem repeat approaches
based on 14 autosomal loci plus amelogenin gender deter-
mination. Data on NVP were collected in 2013 by tele-
phone interview.T
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The ALSPAC sample comprises 12 208 women with
data available on NVP, representing 83.96% of the ori-
ginal study (for more details of the cohort, see ref.29).
Eligible women were all those who were pregnant and resi-
dent in a defined area in South West England, with an ex-
pected date of delivery between 1991 and 1992. The study
website contains details of all the data that are available
through a fully searchable data dictionary [http://www.
bris.ac.uk/alspac/researchers/data-access/data-dictionary].
Data were collected through self-report questionnaires,
with NVP data collected on up to four occasions during
the index pregnancy (at enrolment and at 18 and 32 weeks
of gestation) and 8 weeks after birth.
Lastly, the DNHR30 was initiated in 1977 and holds in-
formation on all treatments at somatic facilities in
Denmark. Information on inpatient treatment is available
since 1977 and on outpatient treatment since 1995. The
register holds information on all women treated specific-
ally for HG in pregnancy (ICD-10 code: O21), as well as
information on gestational age and other pregnancy-
related diagnoses. Additional relevant information was
drawn from the Danish Civil Registration System.30
Women included in the present study were born after
1955, and gave birth to a live-born child between January
1995 and June 2012. Women who had records of HG con-
tributed with information for the first pregnancy/childbirth
with HG diagnoses, which was not necessarily the first
pregnancy ever.
How often have they been followed up?
The aim of the NVP Genetics Consortium is to bring to-
gether the effort and resources of different research groups
who are willing to investigate the proposed research ques-
tions. For this reason, follow-ups will be possible in only
some of the cohorts that are participating, which at the
moment are subsets of women of the QIMR NVP and
QIMR MT cohorts. Specifically, women of the QIMR
NVP reporting severe NVP or HG will be invited to answer
more in-depth questions and to provide saliva samples for
genotyping in the present year. A subset of the women of
the QIMR MT are being contacted again 2 years later,
which will allow checking of the consistency of retrospect-
ive reporting; currently their answers regarding NVP do
not show any discordance.
What has been measured?
The most extensive information on NVP is provided by the
QIMR NVP study, which includes details on severity, dur-
ation and impact for each pregnancy, putative risk factors,
medication use and effectiveness. For each pregnancy,
participants are asked to rate their degree of NVP using
qualifiers including the number of days with NVP during
the pregnancy, impact on normal daily routine, consult-
ation with medical professionals, prescription of medica-
tion, use of nutritional support and weight loss. In the
other two QIMR samples, data on occurrence of NVP,
duration and severity according to the same seven-point
scale were collected for the first pregnancy, last pregnancy
and others. For the GSA and MTR samples, women re-
sponded to questionnaires regarding different aspects of
their health and sexual and reproductive history, including
whether they had suffered from nausea and vomiting dur-
ing any of their pregnancies. Subsequent details about
NVP were collected with reference to the most affected
pregnancy, and included information about the trimester(s)
in which the symptoms took place as well as their severity,
following the method of Zhang et al.11
Women in ALSPAC provided information while preg-
nant about their current pregnancy in the context of ques-
tionnaires and clinic visits. During their pregnancies, these
women were asked whether they were suffering from NVP
and if they were using medication for it. Women in the
DNHR have records of all in- and outpatient visits in the
Danish Hospital system, which can be linked to the ICD-
10 codes and socioeconomic variables.
Women of QIMR AES, QIMR MT, ALSPAC and
DNHR have existing genome-wide data and most women
from QIMR NVP will have it after the first follow-up.
GSA and MTR have collected DNA and some single nu-
cleotide polymorphisms have been genotyped.
Data in all samples were based on self-report and were
retrospective for the Australian, Spanish and Finnish sam-
ples; data from ALSPAC and DNHR women were col-
lected prospectively. NVP presence, severity and duration
from the most affected pregnancy will be the primary
phenotypes used in the consortium analyses. We will use
meta-analysis to combine data across studies with hetero-
geneous phenotypes, to improve power to detect novel as-
sociations. Other lifestyle and health variables have been
collected by these cohorts and will be used for specific/sec-
ondary analyses.25,27–31
What has the NVP Genetics
Consortium found?
The NVP Genetics Consortium has showed heritability es-
timates of 73% (95% CI 57–84%) for occurrence, 51%
(95% CI 36–63%) for duration and 53% (95% CI 38–
65%) for severity of NVP.32 These results are consistent
with those of the Norwegian Twin Panel9 although not re-
ported in their paper; using the tetrachoric correlations
and sample sizes, we used the Mx program33 to estimate
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heritabilities of 53% for NVP and 73% for taking nausea
medication.
Epidemiological analysis of the data offers some infor-
mation that is consistent with previous studies. Table 2 sum-
marizes data on the NVP severity in a five-point scale, the
trimester when NVP was reported and the visit to the hos-
pital because of this problem, when available. It includes
only those women with at least one complete pregnancy.
The generalizability of the results should be interpreted
in the context of each sample. In line with previous stud-
ies,34 around 50% of the participants in the unselected
samples reported experiencing NVP of more than 7 days
which resulted in a disruption of their daily routine during
at least one of their pregnancies. However, the percentage
was higher (95.2%) for women of the QIMR NVP sample,
which was designed to over-sample NVP cases. The preva-
lence was also higher in ALSPAC (86.2%), where partici-
pants were asked if they had experienced any nausea and
vomiting, with no duration or severity specified. In add-
ition, between 74.5% and 98.4% of the participants with
NVP reported experiencing NVP in the first trimester, be-
tween 33% and 69.6% reported NVP in the second
trimester and between 8% and 48.4% in the third trimes-
ter. With regard to the use of health services, 1–22.6% of
participants presented to hospital because of NVP.
Using data from the ALSPAC sample, excluding twin
pregnancies, we examined the relationship between the oc-
currence of NVP, sex of the baby and pregnancy order. As
shown in Figure 1 (Occurrence of NVP across pregnancies,
according to sex of the baby, n¼11 797 singleton pregnan-
cies from ALSPAC sample), NVP is more prevalent as the
number of pregnancies increases and in female pregnancies
(87.7%) vs male pregnancies (86.1%), odds ratio
(OR)¼ 1.14 (95% CI: 1.02–1.27, P¼ 0.02). These results
were consistent with those of other cohorts. For women
from the QIMR NVP cohort, 90.08% female pregnancies
and 89.9% male pregnancies were affected by NVP.
However, since women from this cohort were selected to
over-sample cases, the results may not be generalizable.
Additionally, overall 1.6% women from the DNHR had at
least one record of excessive vomiting during pregnancy
(O21 codes in the ICD-10). Among these the prevalence was
1.8% among pregnancies with a female fetus vs 1.4% with a
male fetus, OR¼1.30 (95% CI: 1.25–1.36, P< 0.0001).
Table 2. NVP severity, trimester in which NVP occurred and attendance at hospital because of NVP (valid %, n), segregated by
sample
NVP QIMR NVPa
(n¼879)
QIMR AESa
(n¼1273)
QIMR MT
(twin data)
(n¼296)
QIMR MT
(singleton
pregnancy)a
(n¼268)
GSAb
(n¼1181)
MTRb
(n¼551)
ALSPACc
(n¼12 208)
DNHRd
(n¼565 486)
NVP severity
No NVP/NVP<7 days, minor
impact
4.8 (39) 47.1 (599) 53.4 (158) 67.2 (180) 40.1 (473) 46.1 (250) 13.08 (1597)e
NVP 7þdays, no medical consult-
ation, minimal impact
9.2 (74) 10 (127) 19.3 (57) 15.7 (42) 30.7 (362) 25.8 (140)
NVP 7þdays, no medication,
minor role impairment
19.4 (156) 23.1 (294) 20.6 (61) 13.4 (36) 25.2 (298) 7 (38)
Medication, no weight loss, mod-
erate role impairment
15.7 (126) 10.3 (131) 2.7 (8) 1.7 (5) 2.3 (27) 16.2 (88)
Medication/IV/feeding tube,
weight loss, major role
impairment
50.9 (410) 9.6 (122) 4.1 (12) 1.7 (5) 1.8 (21) 4.8 (26)
NVP during pregnancy
1st trimester 82 (721) 98.4 (665) 97.1 (134) 96.6 (85) 95.1 (673) 97 (290) 74.5 (8969)
2nd trimester 69.6 (612) 68.2 (461) 52.2 (72) 33 (29) 48.7 (345) 43.1 (129) 47.5 (5040)
3rd trimester 48.4 (425) 38.1 (257) 20.3 (28) 8 (7) 12.1 (86) 29.4 (88) 27.8 (2946)
NVP use of health services 22.6 (199) 21.1 (142) 4.7 (14) 1 (3) 7.5 (53) 7 (20) 1.6 (9074)
QIMR AES, QIMR Australian Endogene Study; QIMR MT, QIMR Mothers of Twins; GSA, Genetics of Sexuality and Aggression; MTR, Murcia Twin
Registry: ALSPAC, Avon Longitudinal Study of Parents and Children; DNHR, Danish National Hospital Register.
aMaximum scores reported across pregnancies.
bReported most affected pregnancy.
cPresent pregnancy.
dFirst pregnancy with excessive NVP.
eALSPAC women reported if they had suffered NVP, regardless of the severity. For this reason, this proportion could be underestimated (it does not include
women with NVP for less than 7 days). A total of 10 611 women (87%) reported NVP.
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Data from the QIMR MT sample showed that women
were more likely to suffer from NVP for more than 7 days
during twin pregnancies (46.62%) as compared with other
reported pregnancies (32.79%), OR¼ 1.79 (95% CI: 1.27–
2.52, p¼ 0.0009). Among those women from the QIMR
NVP cohort with twin pregnancies, however, there was no
difference in the prevalence of NVP in twin pregnancies
(92.45%) vs singleton pregnancies (81.63%), OR¼ 2.76,
95% CI: 0.92–8.3, P¼ 0.07. According to records of the
DNHR, the prevalence of pregnancies presenting with an
ICD-10 diagnosis related to excessive vomiting was twice
as frequent in twin pregnancies (3.0%) as compared with
singleton pregnancies (1.6%), OR¼ 1.92 (95% CI: 1.72–
2.13, p<0.0001). Data from ALSPAC show no difference
in the percentage of symptoms of NVP in women having
twins (91.7%) compared with those having singletons
(86.6%), OR¼ 1.71, 95% CI: 0.97–3.03, p¼0.06.
Figure 2 (NVP severity for the most affected pregnancy
reported by birth order, including data from QIMR NVP,
GSA and MTR, n¼ 1478) shows the severity of NVP of
the most affected reported pregnancy for women in the
GSA, MTR and QIMR NVP samples. Not only the occur-
rence, but also the severity, of NVP is higher as the number
of pregnancies increases. All of these results are similar to
those of other studies.22,24,35
What are the main strengths and
weaknesses?
The collaboration between the researchers in the NVP
Genetics Consortium confers an exceptional possibility to
conduct a systematic examination of the aetiology of NVP
and HG in large samples. Many of these cohorts have exist-
ing genome-wide data or DNA, which will allow us to con-
duct the first GWAS for these traits. Since the participants
come from different cohorts, it will be possible to analyse en-
vironmental risk factors specific to each sample. Moreover,
the most significant work to date on the genetics of NVP and
HG9–11 has focused on case/control style analyses. The data
currently available within the Consortium will also allow
examination of the high variability, the complexity and the
psychosocial correlates and consequences of these conditions.
There are some limitations that will need to be taken
into account. For instance, there may be recall bias in those
women reporting data about NVP from pregnancies that
took place some years ago. As many of the participants
within the cohorts are within child-bearing age, it is pos-
sible that we may be underestimating prevalence and sever-
ity as there is the potential for more affected pregnancies,
and few studies have followed up participants who experi-
enced early pregnancy loss. Because the Consortium is
using existing data from existing studies, not all variables
are available for all studies. The generalizability of some of
the results derived from the Consortium may be limited to
Figure 1. Occurrence of NVP across pregnancies, according to sex of
the baby (n¼ 11 797 singleton pregnancies from ALSPAC sample).
Figure 2. NVP severity for the most affected pregnancy reported by birth order, including data from QIMR NVP, GSA and MTR (n¼ 1478).
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the unselected samples. Last, historical and social back-
ground should be taken into consideration when interpret-
ing the results of our analyses. Despite these limitations,
the participation of different cohorts is an important part
of the richness of the project and will enable both testing
for the heterogeneity and provision of important informa-
tion on the generalizability of the findings.
Can I get hold of the data? Where can I find
out more?
The NVP Genetics Consortium is actively searching for
new groups interested in joining this common effort to elu-
cidate the causes of NVP and HG. The Consortium does
not require researchers to share raw data and, as such, the
Consortium does not hold raw data that can be accessed
by other researchers. However, the Consortium is very
keen to support collaboration and will make results and
summary statistics from genome-wide association analyses
available from the consortium webpage: [https://genepi.
qimr.edu.au/staff/sarahMe/nvp/index.html]. Interested re-
searchers should contact Dr Sarah Medland, whose details
are provided in the contact author information.
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NVP Genetics Consortium in a nutshell
• The NVP Genetics Consortium is an open collabora-
tive network of researchers aiming to study the risk
factors, with a special focus on the genetic factors,
for the development of nausea and vomiting during
pregnancy (NVP), commonly known as morning
sickness.
• Consortium efforts started in 2013. The Consortium
currently brings together cohorts from Australia,
Finland, Spain and the UK, including data from
16756 women of whom 80% reported NVP, and data
from 9074 women who have suffered extreme NVP
from a Danish population registry.
• Some cohorts have existing data available on NVP
and decided to join the Consortium, whereas others
specifically collected data with this aim. Some have
planned follow-ups to enrich the available data. Age
at data collection ranges between 13 and 78.
• The NVP Genetics Consortium is collecting data of
presence, duration and severity of NVP, demo-
graphic and health-related measures. Some of the
samples are already genotyped.
• The NVP Genetics Consortium is actively searching
for new collaborations. Summary data from GWAS
will be made available at the Consortium website.
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